Daiichi Sankyo Taps Japan Government Capital For New Seed Fund
This article was originally published in PharmAsia News
Daiichi Sankyo and Mitsubishi UFJ – with ¥450 million in government backing – launched a fund to develop university venture technology for Daiichi Sankyo’s pipeline.
You may also be interested in...
Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan
YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.